GlassScriptPhysician profile
Carla Gaul
NPI 1861040362
$3,536.37
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $923 · 2022: $1,900 · 2023: $433 · 2024: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $759.05 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $412.50 | 2022-2024 | Farxiga, Breztri |
| Amgen INC. | $290.26 | 2021-2023 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.24 | 2021-2023 | Xifaxan, Trulance |
| Lilly USA, LLC | $225.49 | 2021-2024 | Zepbound, Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $218.27 | 2021-2022 | |
| Glaxosmithkline, LLC. | $188.84 | 2021-2023 | Shingrix, Arexvy, Bexsero |
| Teva Pharmaceuticals USA, INC. | $140.98 | 2022 | |
| Pfizer INC. | $115.75 | 2021-2023 | |
| Novo Nordisk INC | $97.74 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $97.34 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.35 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $62.80 | 2022 | |
| Exact Sciences Corporation | $57.39 | 2023-2024 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $54.51 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $45.75 | 2022 | |
| Vanda Pharmaceuticals INC. | $45.72 | 2022 | |
| Sanofi-Aventis U.S. LLC | $43.75 | 2022 | |
| Collegium Pharmaceutical, INC. | $39.20 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $38.62 | 2021 | |
| Horizon Therapeutics Plc | $35.18 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.14 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.53 | 2022 | |
| Antares Pharma, INC. | $25.16 | 2022 | |
| Sanofi Pasteur INC. | $22.35 | 2022 | |
| Bardy Diagnostics, INC. | $20.62 | 2022 | |
| Amarin Pharma, INC. | $18.90 | 2021 | |
| Medtronic, INC. | $18.80 | 2022 | |
| Neurocrine Biosciences, INC. | $18.72 | 2022 | |
| Radius Health, INC. | $15.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.09 | 2021 | |
| Therapeuticsmd, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Gaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.